ADAM17 and kidney disorder: TMI-1 has been successfully used in mouse models of arthritis and kidney diseases to target and inhibit ADAM-17-mediated TNFα (Tumor Necrosis Factorα) and TGFα (Transforming Growth Factorα) release, respectively.